<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849483</url>
  </required_header>
  <id_info>
    <org_study_id>KHUH 2016-05-201</org_study_id>
    <nct_id>NCT02849483</nct_id>
  </id_info>
  <brief_title>Effect of Ramosetron on Bowel Motility After Gynecological Surgery</brief_title>
  <official_title>Effect of Ramosetron on Postoperative Restoration of Bowel Motility After Gynecological Laparoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ramosetron is effective in preventing postoperative nausea and vomiting. Several studies
      reported that ramosetron is also effective treatment of irritable bowel syndrome. The
      investigators examine the effect of ramosetron on postoperative bowel motility.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ramosetron, a new potent and long-acting selective 5-HT3(5-hydroxytryptamine3) receptor
      anatagonist, is effective for preventing postoperative nausea and vomiting. Also several
      studies reported that ramosetron is effective treatment of diarrhea-predominant irritable
      bowel syndrome because it inhibits the accelerated colonic transit, abnormal colonic water
      transport, defecation abnormality, and the lowered colonic perceptual threshold by
      corticotrophin-releasing hormone, There is no study about the effect of ramosetron used for
      preventing postoperative nausea and vomiting on postoperative bowel motility. In this study,
      the investigators examine the effect of ramosetron on postoperative bowel motility.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from surgery to the passage of first flatus</measure>
    <time_frame>Within 10 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first defecation</measure>
    <time_frame>Within 10 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative ileus</measure>
    <time_frame>Within 10 days after surgery</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence and severity of postoperative nausea</measure>
    <time_frame>0-6 hours, 6-24 hours, and 24-48 hours after surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence and severity of postoperative vomiting</measure>
    <time_frame>0-6 hours, 6-24 hours, and 24-48 hours after surgery</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Ramosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 ml of normal saline iv before induction, ramosetron 0.3 mg iv at the end of surgery, ramosetron 0.6 mg added to the iv PCA(Patient-Controlled Analgesia)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>dexamethasone 10 mg iv before induction, 2 ml of normal saline iv at the end of surgery, 4 ml of normal saline added to the iv PCA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramosetron</intervention_name>
    <description>Administer 2 ml of normal saline iv before induction. Inject ramosetron 0.3 mg iv at the end of surgery. Add ramosetron 0.6 mg to the iv PCA.</description>
    <arm_group_label>Ramosetron</arm_group_label>
    <other_name>Nasea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Administer dexamethasone 10 mg iv before induction. Inject 2 ml of normal saline iv at the end of surgery. Add 4 ml of normal saline to the iv PCA.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-70 yrs of age

          -  ASA(American Society of Anesthesiologists) physical status class I or II

          -  Scheduled for gynecological laparoscopic surgery

        Exclusion Criteria:

          -  Allergic to study drugs

          -  Antiemetics or steroids use within 24 hrs prior to surgery

          -  Dependence upon opioids

          -  Insulin dependent Diabetes Mellitus

          -  Cardiovascular or pulmonary disease

          -  Renal or hepatic insufficiency

          -  BMI&gt;=35kg/m2

          -  History of motion sickness or PONV

          -  Cigarette smoker

          -  Conversion to open laparotomy from laparoscopic surgery

          -  Pregnants
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mi Kyeong Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youngsoon Kim, M.D., Ph.D.</last_name>
    <phone>+82-958-8589</phone>
    <email>ys.kim@khu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youngsoon Kim</last_name>
      <phone>958-8589</phone>
      <email>ys.kim@khu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Mi Kyeong Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>PONV</keyword>
  <keyword>digestive signs and symptoms</keyword>
  <keyword>vomiting</keyword>
  <keyword>antiemetics</keyword>
  <keyword>nausea</keyword>
  <keyword>ramosetron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

